Potassium chloride
- Generic Name
- Potassium chloride
- Brand Names
- Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol
- Drug Type
- Small Molecule
- Chemical Formula
- ClK
- CAS Number
- 7447-40-7
- Unique Ingredient Identifier
- 660YQ98I10
- Background
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.
- Indication
For use as an electrolyte replenisher and in the treatment of hypokalemia.
- Associated Conditions
- Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema
- Associated Therapies
- Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy
Perfusion Medical's PM-208 Receives $1.8 Million Grant from U.S. Air Force for Blood Loss Treatment
• Perfusion Medical secured a $1.8 million grant from the U.S. Air Force to advance PM-208, a novel treatment for massive blood loss injuries, bringing total military support to $7 million since 2023.
• PM-208, developed by VCU's Dr. Martin Mangino, uses a specific formulation of polyethylene glycol to prevent ischemic reperfusion injuries by drawing water into capillaries.
• Phase 1 clinical trials for PM-208 are expected to commence in early 2025, marking a significant step toward potential FDA approval and addressing a critical unmet medical need.
• Preclinical studies in animal models have demonstrated that PM-208 significantly improves survival rates in cases of massive blood loss compared to current treatments like saline or blood transfusions.
Avatar Therapy Shows Promise in Reducing Auditory Hallucinations in Schizophrenia
• Avatar therapy, which involves creating a digital representation of the voices heard by individuals with psychosis, has demonstrated effectiveness in clinical trials.
• A recent study in *Nature Medicine* highlights that this approach can help patients gain control over their auditory hallucinations by engaging with the avatars.
• The therapy has shown potential in reducing suicidal ideation and, in some instances, completely eliminating the voices experienced by patients with schizophrenia.
• Ongoing research in the UK, Australia, and Denmark continues to explore and refine avatar therapy as a treatment for auditory hallucinations.
PAVE-2 Trial: Evaluating Paclitaxel and Sirolimus-Coated Balloons for AV Fistula Patency
• The PAVE-2 trial is a multicenter, randomized controlled study comparing paclitaxel-coated and sirolimus-coated balloons against uncoated balloons for arteriovenous fistula (AVF) maintenance.
• The primary endpoint is time to loss of treatment segment primary patency, focusing on the vein length treated during the initial plain balloon fistuloplasty.
• Secondary endpoints include time to loss of primary patency at any treatment segment, AVF abandonment, total interventions, adverse events, and patient quality of life.
• The trial aims to recruit 642 patients across the UK, assessing the superiority of drug-coated balloons in maintaining AVF patency over a 1-year follow-up period.
Xifaxan Monotherapy Shows Superiority to Lactulose in Reducing Hepatic Encephalopathy Recurrence
• Analysis of two randomized trials reveals that Xifaxan monotherapy is more effective than lactulose in reducing overt hepatic encephalopathy (OHE) recurrence and mortality.
• New data highlights Xifaxan's impact on reducing rehospitalizations for OHE in both commercially insured and Medicare patient populations.
• Plenvu's efficacy as a bowel preparation medication is confirmed in colonoscopy patients with comorbid conditions or those on medications affecting bowel prep quality.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath